KDR and neoplasm: VEGFR-TKIs, such as sunitinib, pazopanib, axitinib, and cabozantinib, inhibit angiogenesis and tumour proliferation by blocking VEGF-mediated signalling pathways, resulting in decreased tumour vascularity and potential volume reduction [12, 13].